Evidence Level:Sensitive: C2 – Inclusion Criteria
Title:
A non-interventional, single-arm, prospective clinical study for the efficacy and safety of gefitinib combined with bevacizumab and pemetrexed in first-line treatment of stage IV EGFR mutant non-squamous non-small cell lung cancer.
Evidence Level:Sensitive: C2 – Inclusion Criteria
Title:
Bevacizumab Plus EGFR-TKIs in Chinese Patients With EGFR-mutant NSCLC: a Real-world Study
Excerpt:...An exon 19 deletion mutation or exon 21 L858R mutation in EGFR has been found clinically, with or without EGFR T790M mutation 5....
More C2 evidence
Evidence Level:Sensitive: C2 – Inclusion Criteria
Title:
Clinical Study of EGFR-TKI Combined with Bevacizumab in Patients with Stage IIIB/IVNon-Small-Cell Lung Cancer Harboring EGFR Mutation and PD-L1 Positive
Excerpt:...The sensitive mutation of EGFR gene (exon 19del, exon L858R) was detected. ...
Evidence Level:Sensitive: C2 – Inclusion Criteria
Title:
Efficacy and Safety of Ametinib Combined With Bevacizumab in First-line Treatment of Non-oligometastatic Advanced NSCLC With EGFR-mutations.
Excerpt:...1) age ≥18 years and ≤75 years; 2) life expectancy of more than 3 months; 3) patients with advanced NSCLC who had histologic or cytological confirmation according to the International Association for the study of lung cancer and the American Joint Committee on Classification of Cancer, 8th edition TNM staging classification of lung cancer; 4) Eastern Cooperative Oncology Group (ECOG) physical status score of 0-1; 5) had not received any previous systemic anti-tumor therapy for advanced disease; if had received prior platinum-based adjuvant chemotherapy, neoadjuvant chemotherapy, and disease progression to stage IV, and had occurred > 6 months after the end of the last treatment, were eligible to participate in this clinical study; 6) had a positive EGFR mutation (including 19 DEL, L858R) confirmed by histiocytogenetic testing; 7) CT or MRI confirmed metastases of more than or equal to 2 organs or single organs > GT 3, and brain metastases included symptomatic, asymptomatic, and meningeal metastases 8) haematological adequacy: absolute neutrophil count ≥1.5 × 10^9 L, platelet count ≥100 × 10^9 L, and hemoglobin ≥90 g/L 9) liver adequacy: total bilirubin level ≤1.5 times the upper limit of normal, aspartate transaminase and Alanine transaminase levels ≤2.5 times the upper limit of normal 10) renal adequacy: defined as creatinine clearance rate ≥50 ml/min (Cockcroft-Gault formula) 11) clotting adequacy: international standard ratio (INR) or prothrombin time (PT)≤1.5 times the upper limit of normal; If the patient is receiving anticoagulant treatment, INR/PT should be within the range of anticoagulant drugs proposed; 12)Female patients need to use efficient contraception and continue for at least 180 days after discontinuing the trial treatment. ...
Evidence Level:Sensitive: C2 – Inclusion Criteria
Title:
Real World Study on Erlotinib/Gefitinib Combined With Bevacizumab in Advanced Non-aquamous Non-small Cell Lung Cancer
Excerpt:...- EGFR mutation(19del/L858R)...
Evidence Level:Sensitive: C2 – Inclusion Criteria
Title:
Study Comparing Bevacizumab + Erlotinib vs Erlotinib Alone as First Line Treatment of Patients With EGFR Mutated Advanced Non Squamous Non Small Cell Lung Cancer
Excerpt:...Activating epidermal growth factor receptor mutation (exon19 deletion or exon 21 L858R mutation or other activating/sensitizing mutations, such as exon 21 L861Q, exon 18 G719S, G719A and G719C, exon 20 S768I and V769L)....
Evidence Level:Sensitive: C2 – Inclusion Criteria
Title:
Clinical Study of Ametinib Combined With Bevacizumab in First-line Treatment of Advanced NSCLC With EGFR-mutations.
Excerpt:...- Non-squamous non-small cell lung cancer (NSCLC) confirmed by pathology (including histology or cytology); ③ EGFR mutation positive (exon 19 deletion or exon 21 L858R mutation); (4) ≥3 intracranial metastases, asymptomatic brain metastases; (5) Never received antitumor therapy before;...
Evidence Level:Sensitive: C2 – Inclusion Criteria
Title:
BELIEF (Bevacizumab and ErLotinib In EGFR Mut+ NSCLC)
Excerpt:...- Centrally confirmed EGFR exon 19 deletion (del19) or exon 21 mutation (L858R)...
Evidence Level:Sensitive: C2 – Inclusion Criteria
Title:
A Study of Tarceva vs. Avastin+Tarceva for Advanced NSCLC With EGFR m(+)
Excerpt:...- Locally diagnosed sensitive EGFR mutation positive (Exon 19 deletion or L858R)...
Evidence Level:Sensitive: C2 – Inclusion Criteria
Title:
Bevacizumab Combined With Gefitinib in the Treatment of Advanced NSCLC
Excerpt:...According to the method of second-generation sequencing, L858R point mutation in exon 21 of EGFR gene was found in primary NSCLC with or without any other coexisting mutations....
Evidence Level:Sensitive: C2 – Inclusion Criteria
Title:
Bevacizumab and Erlotinib in Lung Cancer With Brain Metastases, a Phase II Trial
Excerpt:...- A tumor harboring an EGFR mutation known to be associated with erlotinib sensitivity (exon 19 deletion and L858R)...
Evidence Level:Sensitive: C2 – Inclusion Criteria
Title:
Compare Bevacizumab in Combination With Erlotinib Versus Erlotinib Alone in NSCLC Patients Activating EGFR Mutations
Excerpt:...An exon 19 deletion mutation or exon 21 L858R mutation has been found in high-sensitivity EGFR mutation tests by PCR using tumor tissue centrally confirmed....
Evidence Level:Sensitive: C2 – Inclusion Criteria
Title:
A randomized open-label phase 3 trial comparing bevacizumab + erlotinib vs erlotinib alone as first line treatment of patients with EGFR mutated advanced non squamous non small cell lung cancer. Studio randomizzato, in aperto, di fase 3, di confronto tra bevacizumab + erlotinib vs erlotinib in monoterapia come trattamento di prima linea di pazienti affetti da carcinoma del polmone non a piccole cellule ad istotipo non squamoso e mutazione attivante di EGFR
Excerpt:...Activating epidermal growth factor receptor mutation (exon19 deletion or exon 21L858R mutation or other activating/sensitizing mutations, such as exon 21 L861Q,exon 18 G719S, G719A and G719C, exon 20 S768I and V769L). ...
Evidence Level:Sensitive: C2 – Inclusion Criteria
Title:
Clinical study of gefitinib monotherapy versus gefitinib combined with bevacizumab for advanced NSCLC with positive EGFR 21L858R mutation
Excerpt:...Histologically or cytologically confirmed non-squamous non-small cell lung cancer, and the use of NGS detection suggested an exon mutation in EGFR 21L858R. ...
Evidence Level:Sensitive: C2 – Inclusion Criteria
Title:
Gefitinib plus pemetrexed combined with bevacizumab or carboplatin in first-line treatment of stage IV EGFR mutant non-squamous non-small cell lung cancer.
Less C2 evidence
Evidence Level:Sensitive: C3 – Early Trials
Title:
The different overall survival between single-agent EGFR-TKI treatment and with bevacizumab in non-small cell lung cancer patients with brain metastasis
Excerpt:In univariate analyses, ECOG PS 0–1 (HR 0.44 [95% CI 0.31–0.62]; p < 0.001) and bevacizumab treatment (HR 0.41 [95% CI 0.21–0.78]; p = 0.006) were associated with a prolonged OS whereas EGFR L858R mutation (HR 1.49 [95% CI 1.06–2.09]; p = 0.022)...this study showcased an improved OS of EGFR-TKI plus bevacizumab in a real-world cohort of patients with advanced EGFR-mutant NSCLC in which patients with brain metastasis received most benefit from the regimen.
DOI:https://doi.org/10.1038/s41598-022-08449-w
Evidence Level:Sensitive: C3 – Early Trials
Title:
EGFR-TKI plus bevacizumab versus EGFR-TKI monotherapy for patients with EGFR mutation-positive advanced non-small cell lung cancer-A propensity score matching analysis
Excerpt:In subgroup analysis of patients with an L858R mutation, the combination group showed longer PFS (23.1 vs. 10.7 months; HR = 0.40; p = 0.011) and OS (not reached vs. 40.6 months; HR = 0.27; p = 0.040) than the EGFR-TKI monotherapy group.
DOI:10.1016/j.jfma.2021.03.023
